© 2020 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
CAR T-Cell Therapy
Tisagenlecleucel Demonstrates Favorable Complete Response Rate, Meets Phase II Primary End Point
August 04, 2020
Tisagenlecleucel, a chimeric antigen receptor T-cell therapy, showed evidence of clinical benefit for patients with relapsed or refractory follicular lymphoma, in terms of complete response rate, meeting the primary end point of the phase 2 ELARA clinical trial.
Axi-Cel Retains Its Benefit in a Real-World Setting in Large B-Cell Lymphomas
July 31, 2020
Axicabtagene ciloleucel demonstrated a similar overall response rate in both the trial and non-trial settings as treatment of patients with relapsed or refractory large B-cell lymphoma.
CAR T-Cell Therapy Evolves in Leukemia Treatment Landscape
July 13, 2020
Jae H. Park, MD, discusses the role of chimeric antigen receptor T-cell therapy in leukemias and how he sees this treatment evolving in the coming years.
CAR T Cell Agents Show Variance in Different Lymphoma Subtypes
July 08, 2020
Chimeric antigen receptor T-cell therapy when administered to patients with non-follicular low-grade lymphoma may experience different efficacy outcomes than patients with aggressive B-cell lymphomas, according to a single-institution retrospective data.
FDA Places Clinical Hold on MELANI-01 Trial for CAR T-Cell Therapy
July 07, 2020
The FDA has placed a clinical hold on the MELANI-01 clinical trial evaluating UCARTCS1A, a chimeric antigen receptor T-cell therapy.
Multidrug Combinations and CAR T-Cell Therapies for Heavily Pretreated Multiple Myeloma Shine at ASCO
July 07, 2020
Breakthrough data for systemic therapies in the treatment of various hematologic malignancies impressed attendees at the American Society of Clinical Oncology 2020 Virtual Scientific Program.
Liso-cel Maintains Efficacy in Outpatient Setting for Patients With Large B-Cell Lymphomas
June 25, 2020
Liso-cel administration in the outpatient setting was implemented successfully in 3 clinical trials at academic and nonacademic medical centers.
Researcher Evaluates Next Steps for Incorporating CAR T-Cell Therapy into Solid Tumor Space
June 23, 2020
In an interview with Targeted Oncology, Prasad S. Adusumilli, MD, FACS, discussed how CAR T-cell therapy could play a role in the treatment of solid tumors. He highlighted the current research and next steps planned to move this cellular therapy into the solid tumor treatment landscape.
CD22-Directed CAR Therapy Achieves High CR Rate in R/R CD22+ Hematologic Malignancies
June 19, 2020
A novel CD22-targeted/4-1BB product achieved a high complete response rate in patients with relapse or refractory CDD22-positive cancers.
Evaluating the Potential for CAR T Cells as Treatment of Solid Tumors
June 15, 2020
Prasad S. Adusumilli, MD, FACS, discusses the potential role of chimeric antigen receptor T-cell therapy as treatment of solid tumors now that they have demonstrated safety and efficacy in some Hematologic Malignancies.